文献速递炎症性肠病

综述:炎症性肠病的新型口服靶向治疗

Review article: novel oral-targeted therapies in inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2018-04-19

本文综述了截至2018年3月1日PubMed和Medline检索及手工检索的临床试验,总结新型口服靶向药物治疗炎症性肠病的疗效。溃疡性结肠炎中托法替尼、乌帕替尼、AJM300和奥扎尼莫德达到主要终点;克罗恩病中非戈替尼和拉喹莫德有效;蒙格森和维度氟地姆的试验已终止。

要点

  • 溃疡性结肠炎:托法替尼(JAK1/3抑制剂III期)、乌帕替尼(JAK1抑制剂II期)、AJM300(α4整合素拮抗剂II期)随机对照试验达到主要疗效终点。
  • 溃疡性结肠炎:奥扎尼莫德(S1P受体激动剂II期)也显示出临床缓解。
  • 克罗恩病:非戈替尼(JAK1抑制剂II期)达到主要终点,拉喹莫德(喹诺酮-3-甲酰胺小分子II期)也有效;蒙格森和维度氟地姆的试验已终止。

核心结论

  • 这可能是激动人心的新时代的开端,医生可基于个体化原则为炎症性肠病患者提供多种治疗选择。
  • 为实现这一目标,需要与现有治疗进行头对头研究并获得更长期的安全性数据。

研究设计与样本

  • 综述:检索PubMed和Medline截至2018年3月1日的文献,关键词包括「IBD」「UC」「CD」「inflammatory bowel disease」「ulcerative colitis」「Crohn's disease」与「phase」「study」「trial」「oral」组合。
  • 同时手工检索临床试验注册库、文章参考文献列表以及消化疾病周、欧洲联合胃肠病学周和ECCO大会的会议摘要。

主要发现

  • 溃疡性结肠炎:托法替尼(JAK 1/3抑制剂,III期)、乌帕替尼(JAK 1抑制剂,II期)和AJM300(α4整合素拮抗剂,II期)的随机对照试验达到主要疗效终点。
  • 溃疡性结肠炎:奥扎尼莫德(S1P受体激动剂,II期)也显示出临床缓解。
  • 克罗恩病:非戈替尼(JAK1抑制剂,II期)达到主要终点,拉喹莫德(喹诺酮-3-甲酰胺小分子,II期)也有效。
  • 使用蒙格森(SMAD7抑制剂)和维度氟地姆(二氢乳清酸脱氢酶抑制剂)的试验已终止。

局限性

  • 需要与现有治疗进行头对头研究,并获得更长期的安全性数据,才能使多种治疗选择用于个体化治疗成为可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a great unmet clinical need for efficacious, tolerable, economical and orally administrated drugs for the treatment of inflammatory bowel disease (IBD). New therapeutic avenues have become possible including the development of medications that target specific genetic pathways found to be relevant in other immune mediated diseases. AIMS: To provide an overview of recent clinical trials for new generation oral targeted medications that may have a future role in IBD management. METHODS: Pubmed and Medline searches were performed up to 1 March 2018 using keywords: "IBD", "UC", "CD", "inflammatory bowel disease" "ulcerative colitis", "Crohn's disease" in combination with "phase", "study", "trial" and "oral". A manual search of the clinical trial register, article reference lists, abstracts from meetings of Digestive Disease Week, United European Gastroenterology Week and ECCO congress were also conducted. RESULTS: In randomised controlled trials primary efficacy endpoints were met for tofacitinib (JAK 1/3 inhibitor-phase III), upadacitinib (JAK 1 inhibitor-phase II) and AJM300 (α4-integrin antagonist-phase II) in ulcerative colitis. Ozanimod (S1P receptor agonist-phase II) also demonstrated clinical remission. For Crohn's disease, filgotinib (JAK1 inhibitor-phase II) met primary endpoints and laquinimod (quinolone-3-carboxide small molecule-phase II) was also efficacious. Trials using mongersen (SMAD7 inhibitor) and vidofludimus (dihydroorotate dehydrogenase inhibitor) have been halted. CONCLUSIONS: This is potentially the start of an exciting new era in which multiple therapeutic options are at the disposal of physicians to treat IBD on an individualised basis. Head-to-head studies with existing treatments and longer term safety data are needed for this to be possible.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. White JR, Phillips F, Monaghan T, et al. Review article: novel oral-targeted therapies in inflammatory bowel disease. Aliment Pharmacol Ther. 2018. PMID: 29672874. doi:10.1111/apt.14669

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。